AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
GM Takes $6 Billion EV Write-Down as Electric Vehicle Demand Slows in the U.S. 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
Ford Targets Level 3 Autonomous Driving by 2028 with New EV Platform and AI Innovations 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
SK Hynix Shares Hit Record High as AI Memory Demand Fuels Semiconductor Rally 
OKLAHOMA CITY, Oct. 25, 2017 -- Federman & Sherwood announces that on October 23, 2017, a class action lawsuit was filed in the United States District Court for the District of New Jersey against Antares Pharma, Inc. (NASDAQ:ATRS). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is December 21, 2016 through October 12, 2017.
Plaintiff seeks to recover damages on behalf of all Antares Pharma, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Friday, December 22, 2017 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.
If you wish to discuss this action, obtain further information and participate in this or any other securities litigation, or should you have any questions or concerns regarding this notice or preservation of your rights, please contact:
Robin Hester
FEDERMAN & SHERWOOD
10205 North Pennsylvania Avenue
Oklahoma City, OK 73120
Email to: [email protected]
Or, visit the firm’s website at www.federmanlaw.com
